nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—Memory loss—Fluorouracil—head and neck cancer	0.0223	0.0247	CcSEcCtD
Maraviroc—Septic shock—Fluorouracil—head and neck cancer	0.0217	0.024	CcSEcCtD
Maraviroc—Bronchopneumonia—Docetaxel—head and neck cancer	0.0217	0.024	CcSEcCtD
Maraviroc—Diarrhoea haemorrhagic—Docetaxel—head and neck cancer	0.0188	0.0207	CcSEcCtD
Maraviroc—Angina unstable—Docetaxel—head and neck cancer	0.0188	0.0207	CcSEcCtD
Maraviroc—Dysaesthesia—Fluorouracil—head and neck cancer	0.0152	0.0168	CcSEcCtD
Maraviroc—Polyneuropathy—Docetaxel—head and neck cancer	0.0145	0.0161	CcSEcCtD
Maraviroc—Parkinsonism—Fluorouracil—head and neck cancer	0.0144	0.016	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—STAT6—head and neck cancer	0.0142	0.149	CbGpPWpGaD
Maraviroc—Bone marrow depression—Hydroxyurea—head and neck cancer	0.0135	0.0149	CcSEcCtD
Maraviroc—Neuritis—Vinblastine—head and neck cancer	0.0134	0.0148	CcSEcCtD
Maraviroc—Hepatotoxicity—Hydroxyurea—head and neck cancer	0.0118	0.0131	CcSEcCtD
Maraviroc—Rash generalised—Docetaxel—head and neck cancer	0.0111	0.0123	CcSEcCtD
Maraviroc—Rectal haemorrhage—Vinblastine—head and neck cancer	0.0111	0.0122	CcSEcCtD
Maraviroc—Dysaesthesia—Docetaxel—head and neck cancer	0.011	0.0121	CcSEcCtD
Maraviroc—Ulcer—Hydroxyurea—head and neck cancer	0.00964	0.0107	CcSEcCtD
Maraviroc—Neoplasm—Vinblastine—head and neck cancer	0.00904	0.00999	CcSEcCtD
Maraviroc—Neoplasm—Hydroxyurea—head and neck cancer	0.00825	0.00912	CcSEcCtD
Maraviroc—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.00817	0.00903	CcSEcCtD
Maraviroc—Deafness—Vinblastine—head and neck cancer	0.00811	0.00897	CcSEcCtD
Maraviroc—Polyp—Docetaxel—head and neck cancer	0.00779	0.00861	CcSEcCtD
Maraviroc—Cerebrovascular accident—Vinblastine—head and neck cancer	0.00741	0.00819	CcSEcCtD
Maraviroc—Hepatic failure—Hydroxyurea—head and neck cancer	0.00737	0.00814	CcSEcCtD
Maraviroc—Renal failure acute—Hydroxyurea—head and neck cancer	0.00717	0.00793	CcSEcCtD
Maraviroc—Herpes simplex—Fluorouracil—head and neck cancer	0.00712	0.00787	CcSEcCtD
Maraviroc—Cyst—Docetaxel—head and neck cancer	0.00709	0.00784	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00709	0.0743	CbGpPWpGaD
Maraviroc—Ulcer—Fluorouracil—head and neck cancer	0.00694	0.00767	CcSEcCtD
Maraviroc—Inflammation—Fluorouracil—head and neck cancer	0.00677	0.00748	CcSEcCtD
Maraviroc—Neuritis—Docetaxel—head and neck cancer	0.00635	0.00702	CcSEcCtD
Maraviroc—Scotoma—Docetaxel—head and neck cancer	0.00624	0.0069	CcSEcCtD
Maraviroc—Hepatotoxicity—Docetaxel—head and neck cancer	0.00614	0.00678	CcSEcCtD
Maraviroc—Angina pectoris—Vinblastine—head and neck cancer	0.00611	0.00676	CcSEcCtD
Maraviroc—Otitis media—Docetaxel—head and neck cancer	0.00609	0.00673	CcSEcCtD
Maraviroc—Breast disorder—Hydroxyurea—head and neck cancer	0.00598	0.00661	CcSEcCtD
Maraviroc—Pancytopenia—Vinblastine—head and neck cancer	0.00596	0.00659	CcSEcCtD
Maraviroc—Myocardial ischaemia—Docetaxel—head and neck cancer	0.00589	0.00652	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00584	0.0611	CbGpPWpGaD
Maraviroc—Pancreatitis—Hydroxyurea—head and neck cancer	0.00561	0.0062	CcSEcCtD
Maraviroc—Depression—Vinblastine—head and neck cancer	0.00558	0.00617	CcSEcCtD
Maraviroc—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00551	0.0061	CcSEcCtD
Maraviroc—Myocardial infarction—Vinblastine—head and neck cancer	0.00548	0.00606	CcSEcCtD
Maraviroc—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00548	0.00606	CcSEcCtD
Maraviroc—Pancytopenia—Hydroxyurea—head and neck cancer	0.00543	0.00601	CcSEcCtD
Maraviroc—Neutropenia—Hydroxyurea—head and neck cancer	0.00535	0.00591	CcSEcCtD
Maraviroc—Agranulocytosis—Vinblastine—head and neck cancer	0.00522	0.00577	CcSEcCtD
Maraviroc—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00521	0.00576	CcSEcCtD
Maraviroc—Oliguria—Docetaxel—head and neck cancer	0.00514	0.00568	CcSEcCtD
Maraviroc—Infestation NOS—Hydroxyurea—head and neck cancer	0.0051	0.00564	CcSEcCtD
Maraviroc—Infestation—Hydroxyurea—head and neck cancer	0.0051	0.00564	CcSEcCtD
Maraviroc—Amnesia—Fluorouracil—head and neck cancer	0.00507	0.00561	CcSEcCtD
Maraviroc—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.005	0.00553	CcSEcCtD
Maraviroc—Pharyngitis—Vinblastine—head and neck cancer	0.00498	0.00551	CcSEcCtD
Maraviroc—Stomatitis—Hydroxyurea—head and neck cancer	0.00497	0.0055	CcSEcCtD
Maraviroc—Inflammation—Docetaxel—head and neck cancer	0.00488	0.0054	CcSEcCtD
Maraviroc—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00482	0.00533	CcSEcCtD
Maraviroc—Respiratory failure—Docetaxel—head and neck cancer	0.00482	0.00533	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00475	0.0498	CbGpPWpGaD
Maraviroc—Influenza like illness—Docetaxel—head and neck cancer	0.0046	0.00509	CcSEcCtD
Maraviroc—Hallucination—Hydroxyurea—head and neck cancer	0.00456	0.00504	CcSEcCtD
Maraviroc—Colitis—Docetaxel—head and neck cancer	0.00455	0.00503	CcSEcCtD
Maraviroc—Alopecia—Vinblastine—head and neck cancer	0.00444	0.00491	CcSEcCtD
Maraviroc—Neoplasm—Docetaxel—head and neck cancer	0.00428	0.00474	CcSEcCtD
Maraviroc—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00426	0.00471	CcSEcCtD
Maraviroc—Angiopathy—Hydroxyurea—head and neck cancer	0.00415	0.00459	CcSEcCtD
Maraviroc—Eosinophilia—Fluorouracil—head and neck cancer	0.00408	0.00451	CcSEcCtD
Maraviroc—Alopecia—Hydroxyurea—head and neck cancer	0.00405	0.00447	CcSEcCtD
Maraviroc—Anaemia—Vinblastine—head and neck cancer	0.00404	0.00447	CcSEcCtD
Maraviroc—Angina pectoris—Fluorouracil—head and neck cancer	0.00401	0.00443	CcSEcCtD
Maraviroc—Erythema—Hydroxyurea—head and neck cancer	0.00399	0.00441	CcSEcCtD
Maraviroc—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00395	0.00437	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00391	0.041	CbGpPWpGaD
Maraviroc—Leukopenia—Vinblastine—head and neck cancer	0.00391	0.00433	CcSEcCtD
Maraviroc—Pancytopenia—Fluorouracil—head and neck cancer	0.00391	0.00432	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—IL2—head and neck cancer	0.00391	0.041	CbGpPWpGaD
Maraviroc—Deafness—Docetaxel—head and neck cancer	0.00384	0.00425	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00383	0.00423	CcSEcCtD
Maraviroc—Hepatic failure—Docetaxel—head and neck cancer	0.00383	0.00423	CcSEcCtD
Maraviroc—Convulsion—Vinblastine—head and neck cancer	0.00379	0.00419	CcSEcCtD
Maraviroc—Pneumonia—Fluorouracil—head and neck cancer	0.00369	0.00408	CcSEcCtD
Maraviroc—Anaemia—Hydroxyurea—head and neck cancer	0.00368	0.00407	CcSEcCtD
Maraviroc—Discomfort—Vinblastine—head and neck cancer	0.00368	0.00406	CcSEcCtD
Maraviroc—Infestation NOS—Fluorouracil—head and neck cancer	0.00367	0.00406	CcSEcCtD
Maraviroc—Infestation—Fluorouracil—head and neck cancer	0.00367	0.00406	CcSEcCtD
Maraviroc—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00362	0.004	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—KISS1—head and neck cancer	0.00362	0.0379	CbGpPWpGaD
Maraviroc—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.0036	0.00398	CcSEcCtD
Maraviroc—Myocardial infarction—Fluorouracil—head and neck cancer	0.0036	0.00398	CcSEcCtD
Maraviroc—Stomatitis—Fluorouracil—head and neck cancer	0.00358	0.00396	CcSEcCtD
Maraviroc—Conjunctivitis—Fluorouracil—head and neck cancer	0.00357	0.00395	CcSEcCtD
Maraviroc—Leukopenia—Hydroxyurea—head and neck cancer	0.00357	0.00394	CcSEcCtD
Maraviroc—Convulsion—Hydroxyurea—head and neck cancer	0.00345	0.00382	CcSEcCtD
Maraviroc—Sinusitis—Fluorouracil—head and neck cancer	0.00344	0.00381	CcSEcCtD
Maraviroc—Agranulocytosis—Fluorouracil—head and neck cancer	0.00343	0.00379	CcSEcCtD
Maraviroc—Anorexia—Vinblastine—head and neck cancer	0.0034	0.00376	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00337	0.00373	CcSEcCtD
Maraviroc—Discomfort—Hydroxyurea—head and neck cancer	0.00335	0.00371	CcSEcCtD
Maraviroc—Rhinitis—Fluorouracil—head and neck cancer	0.0033	0.00365	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—STAT3—head and neck cancer	0.00329	0.0345	CbGpPWpGaD
Maraviroc—Pharyngitis—Fluorouracil—head and neck cancer	0.00327	0.00362	CcSEcCtD
Maraviroc—Oedema—Hydroxyurea—head and neck cancer	0.00325	0.0036	CcSEcCtD
Maraviroc—Infection—Hydroxyurea—head and neck cancer	0.00323	0.00357	CcSEcCtD
Maraviroc—Paraesthesia—Vinblastine—head and neck cancer	0.0032	0.00354	CcSEcCtD
Maraviroc—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00319	0.00353	CcSEcCtD
Maraviroc—Skin disorder—Hydroxyurea—head and neck cancer	0.00316	0.00349	CcSEcCtD
Maraviroc—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00314	0.00347	CcSEcCtD
Maraviroc—Abdominal pain upper—Docetaxel—head and neck cancer	0.00314	0.00347	CcSEcCtD
Maraviroc—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00311	0.0326	CbGpPWpGaD
Maraviroc—Breast disorder—Docetaxel—head and neck cancer	0.00311	0.00344	CcSEcCtD
Maraviroc—Anorexia—Hydroxyurea—head and neck cancer	0.0031	0.00343	CcSEcCtD
Maraviroc—Decreased appetite—Vinblastine—head and neck cancer	0.0031	0.00343	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.0031	0.00342	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.0031	0.00342	CcSEcCtD
Maraviroc—Nasopharyngitis—Docetaxel—head and neck cancer	0.00308	0.0034	CcSEcCtD
Maraviroc—Pain—Vinblastine—head and neck cancer	0.00305	0.00337	CcSEcCtD
Maraviroc—Constipation—Vinblastine—head and neck cancer	0.00305	0.00337	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00303	0.00335	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—GRP—head and neck cancer	0.00298	0.0312	CbGpPWpGaD
Maraviroc—Bronchospasm—Docetaxel—head and neck cancer	0.00292	0.00323	CcSEcCtD
Maraviroc—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00292	0.00323	CcSEcCtD
Maraviroc—Alopecia—Fluorouracil—head and neck cancer	0.00291	0.00322	CcSEcCtD
Maraviroc—Angina pectoris—Docetaxel—head and neck cancer	0.0029	0.0032	CcSEcCtD
Maraviroc—Erythema—Fluorouracil—head and neck cancer	0.00287	0.00317	CcSEcCtD
Maraviroc—Decreased appetite—Hydroxyurea—head and neck cancer	0.00283	0.00313	CcSEcCtD
Maraviroc—Pancytopenia—Docetaxel—head and neck cancer	0.00282	0.00312	CcSEcCtD
Maraviroc—Abdominal pain—Vinblastine—head and neck cancer	0.00282	0.00312	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00281	0.00311	CcSEcCtD
Maraviroc—Fatigue—Hydroxyurea—head and neck cancer	0.00281	0.0031	CcSEcCtD
Maraviroc—Pain—Hydroxyurea—head and neck cancer	0.00278	0.00308	CcSEcCtD
Maraviroc—Constipation—Hydroxyurea—head and neck cancer	0.00278	0.00308	CcSEcCtD
Maraviroc—Neutropenia—Docetaxel—head and neck cancer	0.00278	0.00307	CcSEcCtD
Maraviroc—Pneumonia—Docetaxel—head and neck cancer	0.00267	0.00295	CcSEcCtD
Maraviroc—Anaemia—Fluorouracil—head and neck cancer	0.00265	0.00293	CcSEcCtD
Maraviroc—Infestation NOS—Docetaxel—head and neck cancer	0.00265	0.00293	CcSEcCtD
Maraviroc—Infestation—Docetaxel—head and neck cancer	0.00265	0.00293	CcSEcCtD
Maraviroc—Hypersensitivity—Vinblastine—head and neck cancer	0.00263	0.00291	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.00263	0.0029	CcSEcCtD
Maraviroc—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00261	0.00289	CcSEcCtD
Maraviroc—Renal failure—Docetaxel—head and neck cancer	0.00261	0.00288	CcSEcCtD
Maraviroc—Neuropathy peripheral—Docetaxel—head and neck cancer	0.0026	0.00287	CcSEcCtD
Maraviroc—Myocardial infarction—Docetaxel—head and neck cancer	0.0026	0.00287	CcSEcCtD
Maraviroc—Stomatitis—Docetaxel—head and neck cancer	0.00258	0.00286	CcSEcCtD
Maraviroc—Jaundice—Docetaxel—head and neck cancer	0.00258	0.00286	CcSEcCtD
Maraviroc—Conjunctivitis—Docetaxel—head and neck cancer	0.00258	0.00285	CcSEcCtD
Maraviroc—Body temperature increased—Hydroxyurea—head and neck cancer	0.00257	0.00284	CcSEcCtD
Maraviroc—Leukopenia—Fluorouracil—head and neck cancer	0.00257	0.00284	CcSEcCtD
Maraviroc—Asthenia—Vinblastine—head and neck cancer	0.00256	0.00283	CcSEcCtD
Maraviroc—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00251	0.00277	CcSEcCtD
Maraviroc—Convulsion—Fluorouracil—head and neck cancer	0.00249	0.00275	CcSEcCtD
Maraviroc—Agranulocytosis—Docetaxel—head and neck cancer	0.00247	0.00273	CcSEcCtD
Maraviroc—Myalgia—Fluorouracil—head and neck cancer	0.00244	0.0027	CcSEcCtD
Maraviroc—Diarrhoea—Vinblastine—head and neck cancer	0.00244	0.0027	CcSEcCtD
Maraviroc—Discomfort—Fluorouracil—head and neck cancer	0.00241	0.00267	CcSEcCtD
Maraviroc—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.00241	0.0253	CbGpPWpGaD
Maraviroc—Hypersensitivity—Hydroxyurea—head and neck cancer	0.0024	0.00265	CcSEcCtD
Maraviroc—Rhinitis—Docetaxel—head and neck cancer	0.00239	0.00264	CcSEcCtD
Maraviroc—Pharyngitis—Docetaxel—head and neck cancer	0.00236	0.00261	CcSEcCtD
Maraviroc—Dizziness—Vinblastine—head and neck cancer	0.00236	0.00261	CcSEcCtD
Maraviroc—Urinary tract disorder—Docetaxel—head and neck cancer	0.00235	0.0026	CcSEcCtD
Maraviroc—Oedema—Fluorouracil—head and neck cancer	0.00234	0.00259	CcSEcCtD
Maraviroc—Connective tissue disorder—Docetaxel—head and neck cancer	0.00234	0.00258	CcSEcCtD
Maraviroc—Asthenia—Hydroxyurea—head and neck cancer	0.00233	0.00258	CcSEcCtD
Maraviroc—Urethral disorder—Docetaxel—head and neck cancer	0.00233	0.00258	CcSEcCtD
Maraviroc—Infection—Fluorouracil—head and neck cancer	0.00233	0.00257	CcSEcCtD
Maraviroc—Nervous system disorder—Fluorouracil—head and neck cancer	0.0023	0.00254	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—MAPK3—head and neck cancer	0.00227	0.0238	CbGpPWpGaD
Maraviroc—Vomiting—Vinblastine—head and neck cancer	0.00227	0.00251	CcSEcCtD
Maraviroc—Erythema multiforme—Docetaxel—head and neck cancer	0.00225	0.00249	CcSEcCtD
Maraviroc—Headache—Vinblastine—head and neck cancer	0.00224	0.00247	CcSEcCtD
Maraviroc—Anorexia—Fluorouracil—head and neck cancer	0.00223	0.00247	CcSEcCtD
Maraviroc—Diarrhoea—Hydroxyurea—head and neck cancer	0.00223	0.00246	CcSEcCtD
Maraviroc—Eye disorder—Docetaxel—head and neck cancer	0.00222	0.00246	CcSEcCtD
Maraviroc—Cardiac disorder—Docetaxel—head and neck cancer	0.00221	0.00244	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—MAPK1—head and neck cancer	0.00216	0.0227	CbGpPWpGaD
Maraviroc—Angiopathy—Docetaxel—head and neck cancer	0.00216	0.00239	CcSEcCtD
Maraviroc—Dizziness—Hydroxyurea—head and neck cancer	0.00215	0.00238	CcSEcCtD
Maraviroc—Mediastinal disorder—Docetaxel—head and neck cancer	0.00214	0.00237	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00213	0.00236	CcSEcCtD
Maraviroc—Nausea—Vinblastine—head and neck cancer	0.00212	0.00234	CcSEcCtD
Maraviroc—Insomnia—Fluorouracil—head and neck cancer	0.00212	0.00234	CcSEcCtD
Maraviroc—Paraesthesia—Fluorouracil—head and neck cancer	0.0021	0.00232	CcSEcCtD
Maraviroc—Alopecia—Docetaxel—head and neck cancer	0.0021	0.00232	CcSEcCtD
Maraviroc—Mental disorder—Docetaxel—head and neck cancer	0.00208	0.0023	CcSEcCtD
Maraviroc—Erythema—Docetaxel—head and neck cancer	0.00207	0.00229	CcSEcCtD
Maraviroc—Malnutrition—Docetaxel—head and neck cancer	0.00207	0.00229	CcSEcCtD
Maraviroc—Vomiting—Hydroxyurea—head and neck cancer	0.00207	0.00229	CcSEcCtD
Maraviroc—Rash—Hydroxyurea—head and neck cancer	0.00205	0.00227	CcSEcCtD
Maraviroc—Dermatitis—Hydroxyurea—head and neck cancer	0.00205	0.00227	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—KISS1—head and neck cancer	0.00205	0.0214	CbGpPWpGaD
Maraviroc—Headache—Hydroxyurea—head and neck cancer	0.00204	0.00225	CcSEcCtD
Maraviroc—Decreased appetite—Fluorouracil—head and neck cancer	0.00204	0.00225	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00202	0.00224	CcSEcCtD
Maraviroc—Pain—Fluorouracil—head and neck cancer	0.002	0.00221	CcSEcCtD
Maraviroc—Nausea—Hydroxyurea—head and neck cancer	0.00193	0.00214	CcSEcCtD
Maraviroc—Anaemia—Docetaxel—head and neck cancer	0.00191	0.00212	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—KISS1—head and neck cancer	0.00186	0.0195	CbGpPWpGaD
Maraviroc—Syncope—Docetaxel—head and neck cancer	0.00186	0.00205	CcSEcCtD
Maraviroc—Leukopenia—Docetaxel—head and neck cancer	0.00185	0.00205	CcSEcCtD
Maraviroc—Body temperature increased—Fluorouracil—head and neck cancer	0.00185	0.00205	CcSEcCtD
Maraviroc—Loss of consciousness—Docetaxel—head and neck cancer	0.00182	0.00201	CcSEcCtD
Maraviroc—Cough—Docetaxel—head and neck cancer	0.00181	0.002	CcSEcCtD
Maraviroc—Convulsion—Docetaxel—head and neck cancer	0.00179	0.00198	CcSEcCtD
Maraviroc—Myalgia—Docetaxel—head and neck cancer	0.00176	0.00195	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00175	0.00194	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—HRAS—head and neck cancer	0.00174	0.0182	CbGpPWpGaD
Maraviroc—Hypersensitivity—Fluorouracil—head and neck cancer	0.00173	0.00191	CcSEcCtD
Maraviroc—Oedema—Docetaxel—head and neck cancer	0.00169	0.00187	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—GRP—head and neck cancer	0.00168	0.0177	CbGpPWpGaD
Maraviroc—Infection—Docetaxel—head and neck cancer	0.00168	0.00186	CcSEcCtD
Maraviroc—Shock—Docetaxel—head and neck cancer	0.00166	0.00184	CcSEcCtD
Maraviroc—Nervous system disorder—Docetaxel—head and neck cancer	0.00166	0.00183	CcSEcCtD
Maraviroc—Pruritus—Fluorouracil—head and neck cancer	0.00166	0.00183	CcSEcCtD
Maraviroc—Skin disorder—Docetaxel—head and neck cancer	0.00164	0.00182	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00163	0.017	CbGpPWpGaD
Maraviroc—Anorexia—Docetaxel—head and neck cancer	0.00161	0.00178	CcSEcCtD
Maraviroc—Diarrhoea—Fluorouracil—head and neck cancer	0.0016	0.00177	CcSEcCtD
Maraviroc—Dizziness—Fluorouracil—head and neck cancer	0.00155	0.00171	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00154	0.0017	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—AKT1—head and neck cancer	0.00153	0.0161	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GRP—head and neck cancer	0.00153	0.016	CbGpPWpGaD
Maraviroc—Insomnia—Docetaxel—head and neck cancer	0.00153	0.00169	CcSEcCtD
Maraviroc—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.00152	0.016	CbGpPWpGaD
Maraviroc—Paraesthesia—Docetaxel—head and neck cancer	0.00152	0.00168	CcSEcCtD
Maraviroc—Vomiting—Fluorouracil—head and neck cancer	0.00149	0.00165	CcSEcCtD
Maraviroc—Rash—Fluorouracil—head and neck cancer	0.00148	0.00163	CcSEcCtD
Maraviroc—Dermatitis—Fluorouracil—head and neck cancer	0.00148	0.00163	CcSEcCtD
Maraviroc—Decreased appetite—Docetaxel—head and neck cancer	0.00147	0.00162	CcSEcCtD
Maraviroc—Headache—Fluorouracil—head and neck cancer	0.00147	0.00162	CcSEcCtD
Maraviroc—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.00146	0.0153	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00146	0.00161	CcSEcCtD
Maraviroc—Fatigue—Docetaxel—head and neck cancer	0.00146	0.00161	CcSEcCtD
Maraviroc—Constipation—Docetaxel—head and neck cancer	0.00145	0.0016	CcSEcCtD
Maraviroc—Pain—Docetaxel—head and neck cancer	0.00145	0.0016	CcSEcCtD
Maraviroc—Nausea—Fluorouracil—head and neck cancer	0.00139	0.00154	CcSEcCtD
Maraviroc—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.00139	0.0145	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00138	0.00153	CcSEcCtD
Maraviroc—Body temperature increased—Docetaxel—head and neck cancer	0.00134	0.00148	CcSEcCtD
Maraviroc—Abdominal pain—Docetaxel—head and neck cancer	0.00134	0.00148	CcSEcCtD
Maraviroc—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.00127	0.0133	CbGpPWpGaD
Maraviroc—Hypersensitivity—Docetaxel—head and neck cancer	0.00125	0.00138	CcSEcCtD
Maraviroc—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00122	0.0128	CbGpPWpGaD
Maraviroc—Asthenia—Docetaxel—head and neck cancer	0.00121	0.00134	CcSEcCtD
Maraviroc—Pruritus—Docetaxel—head and neck cancer	0.0012	0.00132	CcSEcCtD
Maraviroc—Diarrhoea—Docetaxel—head and neck cancer	0.00116	0.00128	CcSEcCtD
Maraviroc—Dizziness—Docetaxel—head and neck cancer	0.00112	0.00124	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KISS1—head and neck cancer	0.0011	0.0115	CbGpPWpGaD
Maraviroc—Vomiting—Docetaxel—head and neck cancer	0.00107	0.00119	CcSEcCtD
Maraviroc—Rash—Docetaxel—head and neck cancer	0.00107	0.00118	CcSEcCtD
Maraviroc—Dermatitis—Docetaxel—head and neck cancer	0.00106	0.00118	CcSEcCtD
Maraviroc—Headache—Docetaxel—head and neck cancer	0.00106	0.00117	CcSEcCtD
Maraviroc—Nausea—Docetaxel—head and neck cancer	0.001	0.00111	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GRP—head and neck cancer	0.000904	0.00947	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT6—head and neck cancer	0.000877	0.00919	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—YAP1—head and neck cancer	0.000776	0.00814	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000654	0.00685	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000529	0.00554	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000522	0.00547	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOTCH1—head and neck cancer	0.0005	0.00524	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000486	0.0051	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.00048	0.00503	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2—head and neck cancer	0.000449	0.0047	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000429	0.00449	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2—head and neck cancer	0.000408	0.00427	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—head and neck cancer	0.000371	0.00389	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH1—head and neck cancer	0.00035	0.00367	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAPK3—head and neck cancer	0.000328	0.00343	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTEN—head and neck cancer	0.000324	0.00339	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAPK1—head and neck cancer	0.000312	0.00327	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EGFR—head and neck cancer	0.000312	0.00327	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000298	0.00312	CbGpPWpGaD
Maraviroc—CCR5—Disease—STAT3—head and neck cancer	0.000289	0.00303	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAPK3—head and neck cancer	0.000276	0.0029	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—head and neck cancer	0.000271	0.00284	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAPK1—head and neck cancer	0.000263	0.00276	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGFR—head and neck cancer	0.000263	0.00276	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—HRAS—head and neck cancer	0.00025	0.00262	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—head and neck cancer	0.000243	0.00255	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2—head and neck cancer	0.000241	0.00252	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.00024	0.00252	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000237	0.00248	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCND1—head and neck cancer	0.000235	0.00246	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CA—head and neck cancer	0.000228	0.00239	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.000228	0.00239	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTEN—head and neck cancer	0.000227	0.00237	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000225	0.00235	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT1—head and neck cancer	0.000221	0.00232	CbGpPWpGaD
Maraviroc—CCR5—Disease—HRAS—head and neck cancer	0.000211	0.00221	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFA—head and neck cancer	0.000205	0.00214	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT3—head and neck cancer	0.000203	0.00212	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UROD—head and neck cancer	0.0002	0.0021	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK3—head and neck cancer	0.000194	0.00203	CbGpPWpGaD
Maraviroc—CCR5—Disease—AKT1—head and neck cancer	0.000186	0.00195	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK1—head and neck cancer	0.000184	0.00193	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGFR—head and neck cancer	0.000184	0.00193	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—head and neck cancer	0.00016	0.00167	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—head and neck cancer	0.000155	0.00162	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HRAS—head and neck cancer	0.000148	0.00155	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—head and neck cancer	0.000131	0.00137	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NAT2—head and neck cancer	8.32e-05	0.000871	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—DPYD—head and neck cancer	7.29e-05	0.000764	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—YAP1—head and neck cancer	6.92e-05	0.000725	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TYMS—head and neck cancer	4.16e-05	0.000435	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—head and neck cancer	4.11e-05	0.00043	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPX1—head and neck cancer	3.93e-05	0.000412	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1A1—head and neck cancer	3.89e-05	0.000408	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.32e-05	0.000243	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—head and neck cancer	2.02e-05	0.000212	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.42e-05	0.000149	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—head and neck cancer	1.16e-05	0.000122	CbGpPWpGaD
